FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2736075961> ?p ?o ?g. }

• W2736075961 endingPage "4331" @default.
• W2736075961 startingPage "4331" @default.
• W2736075961 abstract "Abstract Background Loss of chromosome Y (-Y) is observed in 4-10% of male MDS patients as a single cytogenetic abnormality, and is associated to a better outcome. -Y is also known to be an age related phenomenon occurring in 8-10% of elderly men. The clinical significance of -Y in MDS has been a matter of discussion. However, there is increasing evidence that -Y involves the clonal population in MDS cases, and is more likely to be associated with a hematological malignancy when it involves a greater number of metaphases. Aims In this study we aimed to 1) analyze the prognostic impact of -Y in the context of the IPSS-R cytogenetic classification, 2) evaluate the clinical significance of the percentage of metaphases with isolated -Y, 3) test whether finding -Y may predispose to over diagnose MDS in patients with borderline morphological features. Methods We evaluated 3581 male patients from the Spanish Registry of MDS with a diagnosis of MDS or CMML (WHO 2001). Patients with isolated -Y and normal karyotype by conventional cytogenetic analysis were selected. The main study outcomes were survival from diagnosis and transformation into acute myeloid leukemia (AML). Survival curves were drawn using the Kaplan-Meyer method and compared by log-rank test. The cumulative incidence of AML was estimated by taking non AML-related death as a competing risk. Statistical comparisons were done by the Mann-Whitney U-test for continuous data, and the chi-square test for categorical factors. Stata, version 11, software (www.stata.org) was used for the statistical analysis. Results Isolated -Y was identified in 177 patients (-Y group) and compared with the 2246 male patients with normal karyotype (46,XY group). The median age for the whole series was 74 years old (IQR 67-80). -Y patients were found to be older than patients in the 46,XY group with a median (IQR) of 78 (74-83) versus 74 (66-79) years old, respectively (n=0.0001). There was no difference between both groups in terms of hemoglobin concentration, neutrophil and platelet counts at diagnosis. Percentage of bone marrow (BM) blasts was significantly lower in the -Y group (median (IQR): 2(0-3) vs. 2(1-5), respectively; p=0.003). Differences in distribution by WHO 2001 classification of MDS were not found between the two groups. After a follow-up of 2,190 patient-years, 1684 (69.5%) patients had died and the median actuarial survival was 3.6 years (95% C.I, 3.3-3.9). A trend towards a larger median survival in the -Y group versus 46,XY group was observed, since it not reached statistical significance (5.2 years [95% CI, 3.89 to 6.40] versus 4.26 years [95% CI, 3.89 to 4.59], respectively) (P=0. 17; Fig. 1A). After a median follow-up of 1.6 years (IQR: 0.8 - 3.7) from MDS diagnosis, 296 patients had progressed to AML, 901 had died without AML, and 1224 were censored alive without transformation. -Y was associated with a decreased incidence of AML at univariate analysis (figure 1B), and after adjustment for the percentage of BM blasts (SHR: 0.46; 95%CI: 0.24-0.88; p=0.02). Within the -Y group, neither survival nor the risk of leukemic transformation were influenced by the percentage of aberrant metaphases (>75% vs, ≤ 75%). From the whole series, only 6.4% of the cases were classified as not having a MDS strong phenotype, defined by the presence of megakaryocytic dysplasia, more than 5% blasts in the bone marrow, or more than 15% ring sideroblasts. These cases were uniformly distributed between the two groups, suggesting that the better outcome in the -Y group cannot be explained by enrichment in cases misdiagnosed as MDS. Conclusions Our results derived from the largest series of patients with loss of chromosome Y support the current recommendation of classifying patients with -Y within the very good risk category of the IPSS-R for MDS and rule out a selection bias as a possible explanation of this better outcome. An analysis of the molecular basis of MDS with isolated -Y would be of interest as it may provide a biological basis of protection against AML progression. Disclosures No relevant conflicts of interest to declare." @default.
• W2736075961 created "2017-07-21" @default.
• W2736075961 creator A5000776864 @default.
• W2736075961 creator A5003711904 @default.
• W2736075961 creator A5006173909 @default.
• W2736075961 creator A5010010012 @default.
• W2736075961 creator A5017225753 @default.
• W2736075961 creator A5020211212 @default.
• W2736075961 creator A5023726309 @default.
• W2736075961 creator A5026592803 @default.
• W2736075961 creator A5028199476 @default.
• W2736075961 creator A5029161067 @default.
• W2736075961 creator A5030067333 @default.
• W2736075961 creator A5035896968 @default.
• W2736075961 creator A5042537187 @default.
• W2736075961 creator A5045863854 @default.
• W2736075961 creator A5047635203 @default.
• W2736075961 creator A5049511411 @default.
• W2736075961 creator A5052934298 @default.
• W2736075961 creator A5054404140 @default.
• W2736075961 creator A5055139947 @default.
• W2736075961 creator A5056009033 @default.
• W2736075961 creator A5062844986 @default.
• W2736075961 creator A5063154849 @default.
• W2736075961 creator A5063590670 @default.
• W2736075961 creator A5066078964 @default.
• W2736075961 creator A5066103605 @default.
• W2736075961 creator A5068724005 @default.
• W2736075961 creator A5069578009 @default.
• W2736075961 creator A5076013415 @default.
• W2736075961 creator A5083851546 @default.
• W2736075961 date "2016-12-02" @default.
• W2736075961 modified "2023-10-18" @default.
• W2736075961 title "Isolate Loss of Y Chromosome Decreases the Risk of Leukemic Transformation in the Myelodysplastic Syndromes. a Study By the Spanish Group of Myelodysplastic Syndromes" @default.
• W2736075961 doi "https://doi.org/10.1182/blood.v128.22.4331.4331" @default.
• W2736075961 hasPublicationYear "2016" @default.
• W2736075961 type Work @default.
• W2736075961 sameAs 2736075961 @default.
• W2736075961 citedByCount "0" @default.
• W2736075961 crossrefType "journal-article" @default.
• W2736075961 hasAuthorship W2736075961A5000776864 @default.
• W2736075961 hasAuthorship W2736075961A5003711904 @default.
• W2736075961 hasAuthorship W2736075961A5006173909 @default.
• W2736075961 hasAuthorship W2736075961A5010010012 @default.
• W2736075961 hasAuthorship W2736075961A5017225753 @default.
• W2736075961 hasAuthorship W2736075961A5020211212 @default.
• W2736075961 hasAuthorship W2736075961A5023726309 @default.
• W2736075961 hasAuthorship W2736075961A5026592803 @default.
• W2736075961 hasAuthorship W2736075961A5028199476 @default.
• W2736075961 hasAuthorship W2736075961A5029161067 @default.
• W2736075961 hasAuthorship W2736075961A5030067333 @default.
• W2736075961 hasAuthorship W2736075961A5035896968 @default.
• W2736075961 hasAuthorship W2736075961A5042537187 @default.
• W2736075961 hasAuthorship W2736075961A5045863854 @default.
• W2736075961 hasAuthorship W2736075961A5047635203 @default.
• W2736075961 hasAuthorship W2736075961A5049511411 @default.
• W2736075961 hasAuthorship W2736075961A5052934298 @default.
• W2736075961 hasAuthorship W2736075961A5054404140 @default.
• W2736075961 hasAuthorship W2736075961A5055139947 @default.
• W2736075961 hasAuthorship W2736075961A5056009033 @default.
• W2736075961 hasAuthorship W2736075961A5062844986 @default.
• W2736075961 hasAuthorship W2736075961A5063154849 @default.
• W2736075961 hasAuthorship W2736075961A5063590670 @default.
• W2736075961 hasAuthorship W2736075961A5066078964 @default.
• W2736075961 hasAuthorship W2736075961A5066103605 @default.
• W2736075961 hasAuthorship W2736075961A5068724005 @default.
• W2736075961 hasAuthorship W2736075961A5069578009 @default.
• W2736075961 hasAuthorship W2736075961A5076013415 @default.
• W2736075961 hasAuthorship W2736075961A5083851546 @default.
• W2736075961 hasConcept C104317684 @default.
• W2736075961 hasConcept C10515644 @default.
• W2736075961 hasConcept C120665830 @default.
• W2736075961 hasConcept C121332964 @default.
• W2736075961 hasConcept C126322002 @default.
• W2736075961 hasConcept C143998085 @default.
• W2736075961 hasConcept C151730666 @default.
• W2736075961 hasConcept C2779343474 @default.
• W2736075961 hasConcept C2779399171 @default.
• W2736075961 hasConcept C2780007613 @default.
• W2736075961 hasConcept C2780189214 @default.
• W2736075961 hasConcept C2780817109 @default.
• W2736075961 hasConcept C2908647359 @default.
• W2736075961 hasConcept C30481170 @default.
• W2736075961 hasConcept C53226629 @default.
• W2736075961 hasConcept C54355233 @default.
• W2736075961 hasConcept C61511704 @default.
• W2736075961 hasConcept C63363279 @default.
• W2736075961 hasConcept C66339696 @default.
• W2736075961 hasConcept C71924100 @default.
• W2736075961 hasConcept C72563966 @default.
• W2736075961 hasConcept C86803240 @default.
• W2736075961 hasConcept C88879693 @default.
• W2736075961 hasConcept C99454951 @default.
• W2736075961 hasConceptScore W2736075961C104317684 @default.
• W2736075961 hasConceptScore W2736075961C10515644 @default.
• W2736075961 hasConceptScore W2736075961C120665830 @default.
• W2736075961 hasConceptScore W2736075961C121332964 @default.
• W2736075961 hasConceptScore W2736075961C126322002 @default.

• next